Salute e Benessere

With Millions of Children's Lives on the Line, Bill Gates Says Humanity Is at a…

Honors President of the Government of Spain with 2025 Global Goalkeeper Award and 10 champions for their ingenuity and resilience, and for offering hope, solutions in the face of steep funding cuts Honors President of the Government ofSpainwith 2025 Global Goalkeeper Award and 10 champions for their ingenuity and resilience, and for offering hope, solutions in the face of steep funding cuts NEW YORK , Sept. 222025/PRNewswire/ -- At its 2025 Goalkeepers event, Gates Foundation...
PR Newswire
23/09/2025

Prurigo Nodularis market to exhibit growth at a CAGR of 23.2% (2020-2034)…

Key Takeaways from the Prurigo Nodularis Market Report Key Takeaways from the Prurigo Nodularis Market Report Discover which therapies are expected to grab the major prurigo nodularis treatment market share @Prurigo Nodularis Market Report Key Factors Driving the Prurigo Nodularis Market Rising Prurigo Nodularis Disease Prevalence and Awareness The increasing prevalence of prurigo nodularis, particularly among individuals with underlying skin conditions like atopic...
PR Newswire
22/09/2025

GENFIT Reports First-Half 2025 Financial Results and Provides Corporate Update

Cash and cash equivalents totaled €107.5 million as of June 30, 2025, excluding the €26.5 million milestone invoiced in May 2025 (received in July 2025) upon pricing and reimbursement approval of Iqirvo® (elafibranor) in three major European countries€33.5 million in revenues, including the €26.5 million milestone invoiced in May 2025Strong 1H25 sales trajectory reported by Ipsen for Iqirvo® in PBC in July, followed by U.S. market exit of key competitor in SeptemberFollowing...
Nasdaq GlobeNewswire
22/09/2025

IBA – Transparency Notification

(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)Louvain-la-Neuve (Belgium), 22 September 2025, 06:00 PM Summary of the notificationIBA (Ion Beam Applications S.A - EURONEXT - Reuters IBAB.BR - Bloomberg IBAB.BB), the world leader in particle accelerator technology, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further...
Nasdaq GlobeNewswire
22/09/2025

Guerbet : Change in General Management

Change in General ManagementVillepinte France, September 22nd, 2025: Guerbet(FR0000032526 GBT),a global specialist in contrast agents and solutions for medical imaging, announces the appointment of Mr. Jérôme Estampes as interim Chief Executive Officer. Jérôme Estampes replaces Mr. David Hale, who is leaving the Group to pursue new projects. The Board of Directors thanks him for his work since joining Guerbet in February 2018, initially as Chief Commercial Officer and then as...
Nasdaq GlobeNewswire
22/09/2025

Lab Automation Market is Projected To Reach US$8.71 Billion By 2031 at CAGR of…

Check valuable insights in the Lab Automation Market report. You can easily get a sample PDF of the report -https://www.theinsightpartners.com/sample/TIPHE100001249/ Check valuable insights in the Lab Automation Market report. You can easily get a sample PDF of the report -https://www.theinsightpartners.com/sample/TIPHE100001249/ Overview of Report Findings 1. Market Dynamics and Insights:Laboratories are under pressure to improve operational efficiency while remaining...
PR Newswire
22/09/2025

Parkinson's Disease Therapeutics Market Size to Hit US$ 12.83 Billion by 2033…

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/parkinsons-disease-therapeutics-market Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/parkinsons-disease-therapeutics-market Parkinson's NSW calls Parkinson's disease an emerging pandemic, with global cases doubling from 1990 to 2015 to over 6.2 million, and...
PR Newswire
22/09/2025

RNA-based Therapies Market to Reach USD 213.54 Billion by 2033, Driven by Rare…

However, the industry faces challenges such as high development costs, scalability hurdles, stringent regulatory pathways, and safety concerns. Despite these restraints, opportunities are expanding in oncology, cardiometabolic disorders, immunology, and rare diseases, driven by innovations such as self-amplifying RNA and small activating RNA platforms. However, the industry faces challenges such ashigh development costs, scalability hurdles, stringent regulatory pathways, and safety concerns...
PR Newswire
22/09/2025

Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global…

Angelini Pharma secures exclusive option to license global development and commercialization rights for SVG105 1, a pre-clinical investigational novel compound with broad potential to treat brain health diseases, excluding the Republic of Korea, China, Hong Kong, Macau and TaiwanSovargen receives upfront payment and is eligible for future milestone-dependent payments and royaltiesAgreement further expands Angelini Pharma’s strong portfolio and deep therapeutic expertise in brain health,...
Nasdaq GlobeNewswire
22/09/2025

Neuraxpharm participates in ECTRIMS, reinforcing its commitment to multiple…

Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, commented: "Our participation in ECTRIMS reflects the company's commitment to advancing care in multiple sclerosis and our aspiration to expand access to innovative therapies. Providing differentiated products to patients and healthcare professionals across Europe and other markets is a key pillar of Neuraxpharm's growth strategy and allows us to continue strengthening our position as a CNS specialist." Dr. Jörg- Thomas Dierks, CEO of…
PR Newswire
22/09/2025

Antibiotics Market Size to Surpass USD 55.26 Billion by 2033, Report by DataM…

The rising prevalence of infectious diseases is significantly driving the global antibiotics market growth. The rising prevalence of infectious diseases is significantly driving the global antibiotics market growth. The growing incidence of infectious disorders like sepsis, pneumonia, TB, and UTIs is a major factor propelling the worldwide antibiotics market. There is a great need for efficient therapies since hospital-acquired infections, international travel, and growing urbanization...
PR Newswire
22/09/2025

Hon'ble CM of Delhi, Smt. Rekha Gupta, Inaugurates Apollo Athenaa - Asia's First…

In the recent past, more women than men have been diagnosed with cancer, notably with cancers in women accounting for the highest incidence. A new study from ICMR's National Cancer Registry Programme (NCRP) has revealed that breast and cervical cancers are the most common types of cancers among Indian women. In the recent past,more women than menhave been diagnosed with cancer, notably with cancers in women accounting for the highest incidence. A new study fromICMR's National Cancer...
PR Newswire
22/09/2025

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center…

LONDON and NEW YORK, Sept.22, 2025(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announced plans for the next stage of clinical development for its lead drug candidate, urcosimod, to treat neuropathic corneal pain (NCP).The...
Nasdaq GlobeNewswire
22/09/2025

Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market…

Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the commencement of its U.S. operations with the launch of its proprietary Sky Premium Life food supplements brand.All Sky Premium Life products sold in the United States are manufactured locally in GMP-certified, FDA-registered, and UL-audited U.S. facilities, underscoring the Company’s commitment to regulatory excellence and...
Nasdaq GlobeNewswire
22/09/2025

SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of…

As part of the agreement, SOPHiA GENETICS will roll out a Privileged Access Program to selected clinical laboratories specializing in breast and prostate cancer research to validate sensitivity in a real-world setting, with broader commercial availability expected in 2026, alongside a multi-center real-world evidence study to further test its effectiveness. SOPHiA GENETICS's global network will also help drive adoption of advanced PIK3CA/AKT1/PTEN testing in both tissue and liquid biopsy to…
PR Newswire
22/09/2025

Lusochimica S.p.A. (Menarini Group) awarded by the European Commission with the…

The SmartNEBI project is managed by HaDEA, an executive agency of the European Commission, and funded under EU4Health, the EU funding programme designed, amongst other objectives, to tackle cross-border health challenges through high-quality, innovative projects in the health sector. This endorsement highlights SmartNEBI's strategic contribution to the objectives of the Strategic Technologies for Europe Platform (STEP) and recognizes its value for Europe's technological and industrial…
PR Newswire
22/09/2025

Beauty and Well-being Businesses Looking to Expand Product Portfolio Will Be…

COSMEX will also house COSMEX The Secret Chat, seminars and workshops designed to share insights, ideas, skills, and inspiration. COSMEX will also houseCOSMEX The Secret Chat, seminars and workshops designed to share insights, ideas, skills, and inspiration. COSMEX is co-located within-cosmeticsAsia , the leading event inAsia Pacificfor personal care ingredients. Pre-registration is available atwww.cosmexshow.com. For inquiries, email tocontactcenter@rxtradex.comor...
PR Newswire
22/09/2025

European Medicines Agency Recommends Marketing Authorization of AVT03…

REYKJAVIK, ICELAND (September 22, 2024)— Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion recommending approval for AVT03, Alvotech’s proposed biosimilar to Prolia® (denosumab 60 mg/mL single use pre-filed syringe) and Xgeva® (denosumab 70 mg/mL single use…
Nasdaq GlobeNewswire
22/09/2025

First European Participants Randomized in AskBio Phase 2 Gene Therapy Trial of…

Research Triangle Park, N.C., Sept.22, 2025(GLOBE NEWSWIRE) -- AB-1005, a glial cell line-derived neurotrophic factor (GDNF) investigational gene therapy, is being evaluated for the treatment of moderate-stage Parkinson’s disease in the REGENERATE-PD trial Sites in Poland and the United Kingdom have started randomizing participants, with sites in Germany actively screening and following shortly AskBio initiated recruitment in the United States in 2024 , with...
Nasdaq GlobeNewswire
22/09/2025

Biotic innovation tackles iron deficiency in women - now recognized across three…

Iron deficiency is one of the world's most pressing nutritional challenges, affecting over 30% of women of reproductive age globally. Rather than simply adding more iron, Probi's patented strain helps the body absorb it more effectively. LP299V® supports iron uptake in two key ways: by keeping iron in its absorbable form and by increasing the body's expression of iron-converting enzymes. This leads to better absorption from food and supplements. "Recognition across three...
PR Newswire
22/09/2025

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s…

REYKJAVIK, ICELAND and LONDON, UK (September 22, 2025)— Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use...
Nasdaq GlobeNewswire
22/09/2025

Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor…

Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked TrialOculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the upcoming presentation of the positive Phase 2 ACUITY trial results investigating...
Nasdaq GlobeNewswire
22/09/2025

Sweet Tooth by Sabrina Carpenter Fragrances Now Shipping Direct-to-Consumer in…

"At Scent Beauty, we're committed to delivering the best fragrance and beauty experiences to consumers around the world," says Steve Mormoris, CEO of Scent Beauty. "We believe everyone deserves easy, affordable, and environmentally responsible ways to shop. We are excited to announce that Sabrina Carpenter's Sweet Tooth fragrance line now ships directly to customers in the UK and European Union, fulfilled from regional warehouses. We are proud to be a first-mover in this space…
PR Newswire
22/09/2025

Amorepacific Presents AI-based Skin Science Innovations and Findings at IFSCC…

Established in 1959, the IFSCC Congress is the world's largest cosmetics science conference serving as a forum for leading cosmetic researchers around the world. This year's event, themed "The Future is Science," featured two oral presentations and five poster presentations by Amorepacific researchers, aimed at further accelerating biological research on aging and integration of AI in driving scientific advancements. Established in 1959, the IFSCC Congress is the world's largest…
PR Newswire
22/09/2025
Altri  Comunicati